A nationwide study of mechanisms conferring reduced susceptibility to extended-spectrum cephalosporins in clinical Escherichia coli and Klebsiella spp. isolates

References

• NORM/NORM-VET 2000. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø, Oslo; 2001. Available at: http://www.vetinst.no/eng/Publications/Norm-Norm-Vet-Report (accessed July 2012).
   Google Scholar
• NORM/NORM-VET 2010. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø, Oslo; 2011. Available at: http://www.vetinst.no/eng/Publications/Norm-Norm-Vet-Report (accessed July 2012).
   Google Scholar
• Naseer U, Sundsfjord A. The CTX-M conundrum: dissemination of plasmids and Escherichia coli clones. Microb Drug Resist 2011;17:83–97.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;14:413–20.
   PubMed Web of Science ®Google Scholar
• Livermore DM. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557–84.
   PubMed Web of Science ®Google Scholar
• Mulvey MR, Bryce E, Boyd DA, Ofner-Agostini M, Land AM, Simor AE, . Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother 2005;49:358–65.
   PubMed Web of Science ®Google Scholar
• Clarke B, Hiltz M, Musgrave H, Forward KR. Cephamycin resistance in clinical isolates and laboratory-derived strains of Escherichia coli, Nova Scotia, Canada. Emerg Infect Dis 2003;9:1254–9.
   PubMed Web of Science ®Google Scholar
• Mammeri H, Eb F, Berkani A, Nordmann P. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital. J Antimicrob Chemother 2008;61:498–503.
   PubMed Web of Science ®Google Scholar
• Jørgensen RL, Nielsen JB, Friis-Møller A, Fjeldsøe-Nielsen H, Schonning K. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype. J Antimicrob Chemother 2010;65:460–4.
   PubMed Web of Science ®Google Scholar
• Haldorsen B, Aasnaes B, Dahl KH, Hanssen AM, Simonsen GS, Walsh TR, . The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J Antimicrob Chemother 2008;62: 694–702.
   PubMed Web of Science ®Google Scholar
• Bogaerts P, Rodriguez-Villalobos H, Bauraing C, Deplano A, Laurent C, Berhin C, . Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered at two Belgian hospitals. Pathol Biol (Paris) 2010;58:78–83.
   PubMed Web of Science ®Google Scholar
• Gheorghiu R, Yuan M, Hall LM, Livermore DM. Bases of variation in resistance to beta-lactams in Klebsiella oxytoca isolates hyperproducing K1 beta-lactamase. J Antimicrob Chemother 1997;40:533–41.
   PubMed Web of Science ®Google Scholar
• Mammeri H, Poirel L, Nordmann P. In vivo selection of a chromosomally encoded beta-lactamase variant conferring ceftazidime resistance in Klebsiella oxytoca. Antimicrob Agents Chemother 2003;47:3739–42.
   PubMed Web of Science ®Google Scholar
• Kallman O, Giske CG, Samuelsen O, Wretlind B, Kalin M, Olsson-Liljequist B. Interplay of efflux, impermeability, and AmpC activity contributes to cefuroxime resistance in clinical, non-ESBL-producing isolates of Escherichia coli. Microb Drug Resist 2009;15:91–5.
   PubMed Web of Science ®Google Scholar
• Schumacher H, Skibsted U, Skov R, Scheibel J. Cefuroxime resistance in Escherichia coli. Resistance mechanisms and prevalence. APMIS 1996;104:531–8.
   Google Scholar
• Lee CH, Chia JH, Chu C, Wu TL, Liu JW, Su LH. In vivo selection of OmpK35-deficient mutant after cefuroxime therapy for primary liver abscess caused by Klebsiella pneumoniae. J Antimicrob Chemother 2006;58:857–60.
   PubMed Web of Science ®Google Scholar
• Domenech-Sanchez A, Martinez-Martinez L, Hernandez-Alles S, del Carmen Conejo M, Pascual A, Tomas JM, . Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother 2003;47: 3332–5.
   PubMed Web of Science ®Google Scholar
• Schumacher H, Skibsted U, Hansen DS, Scheibel J. Cefuroxime resistance in Klebsiella pneumoniae. Susceptibility to cefotaxime and ceftazidime despite production of ESBLs. APMIS 1997;105:708–16.
   PubMed Web of Science ®Google Scholar
• Nelson EC, Segal H, Elisha BG. Outer membrane protein alterations and blaTEM-1 variants: their role in beta-lactam resistance in Klebsiella pneumoniae. J Antimicrob Chemother 2003;52:899–903.
   PubMed Web of Science ®Google Scholar
• Kallman O, Fendukly F, Karlsson I, Kronvall G. Contribution of efflux to cefuroxime resistance in clinical isolates of Escherichia coli. Scand J Infect Dis 2003;35:464–70.
   PubMed Web of Science ®Google Scholar
• Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997;41:563–9.
   PubMed Web of Science ®Google Scholar
• Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009;63: 659–67.
   PubMed Web of Science ®Google Scholar
• Elliott E, Brink AJ, van Greune J, Els Z, Woodford N, Turton J, . In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006;42:e95–8.
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez L, Pascual A, Hernandez-Alles S, Alvarez-Diaz D, Suarez AI, Tran J, . Roles of beta- lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999;43:1669–73.
   PubMed Web of Science ®Google Scholar
• Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodriguez MC, Velasco M, . Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008;32:534–7.
   PubMed Web of Science ®Google Scholar
• Palasubramaniam S, Subramaniam G, Muniandy S, Parasakthi N. Extended-spectrum beta-lactam resistance due to AmpC hyperproduction and CMY-2 coupled with the loss of OMPK35 in Malaysian strains of Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2007;13: 186–90.
   PubMed Web of Science ®Google Scholar
• Webster DP, Gaulton T, Woodford N, Pike R, Turton J, Perry C, . Emergence of carbapenem resistance due to porin loss in an extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy. Int J Antimicrob Agents 2010;36:575–6.
   PubMed Web of Science ®Google Scholar
• Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, . High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin–tazobactam in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2000;44:362–7.
   PubMed Web of Science ®Google Scholar
• Weber DA, Sanders CC, Bakken JS, Quinn JP. A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance in Escherichia coli. J Infect Dis 1990;162:460–5.
   PubMed Web of Science ®Google Scholar
• Wu TL, Siu LK, Su LH, Lauderdale TL, Lin FM, Leu HS, . Outer membrane protein change combined with co-existing TEM-1 and SHV-1 beta-lactamases lead to false identification of ESBL-producing Klebsiella pneumoniae. J Antimicrob Chemother 2001;47:755–61.
   PubMed Web of Science ®Google Scholar
• Naseer U, Haldorsen B, Simonsen GS, Sundsfjord A. Sporadic occurrence of CMY-2-producing multidrug- resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect 2010;16:171–8.
   PubMed Web of Science ®Google Scholar
• Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, . Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007;45:199–205.
   PubMed Web of Science ®Google Scholar
• NORM/NORM-VET 2004. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø, Oslo; 2005. Available at: http://www.vetinst.no/eng/Publications/Norm-Norm-Vet-Report (accessed July 2012).
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing .Clinical breakpoints. Table v. 1.3, valid from 2011-01-05. EUCAST; 2011.
   Google Scholar
• Black JA, Thomson KS, Buynak JD, Pitout JD. Evaluation of beta-lactamase inhibitors in disk tests for detection of plasmid-mediated AmpC beta-lactamases in well-characterized clinical strains of Klebsiella spp. J Clin Microbiol 2005;43: 4168–71.
   PubMed Web of Science ®Google Scholar
• Steward CD, Rasheed JK, Hubert SK, Biddle JW, Raney PM, Anderson GJ, . Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol 2001;39:2864–72.
   PubMed Web of Science ®Google Scholar
• Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002;40:2153–62.
   PubMed Web of Science ®Google Scholar
• Courpon-Claudinon A, Lefort A, Panhard X, Clermont O, Dornic Q, Fantin B, . Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect 2011;17:557–65.
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez L, Conejo MC, Pascual A, Hernandez-Alles S, Ballesta S, Ramirez De Arellano-Ramos E, . Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles. Antimicrob Agents Chemother 2000;44:2534–6.
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez L. Extended-spectrum beta-lactamases and the permeability barrier. Clin Microbiol Infect 2008; 14(Suppl 1):82–9.
   PubMedGoogle Scholar